Journal
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
Volume 16, Issue 2, Pages 92-97Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1529-8027.2011.00330.x
Keywords
disability; intravenous immunoglobulin; multifocal motor neuropathy; muscle strength; subcutaneous immunoglobulin
Categories
Funding
- PHOCUS Services Ltd.
- CSL Behring
- CSL Behring AG, Berne, Switzerland
Ask authors/readers for more resources
Intravenous immunoglobulin (IVIG) is the first-line therapy for multifocal motor neuropathy (MMN). This open-label multi-centre study (NCT00701662) assessed the efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG)in patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients (42-66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to previous IVIG using a smooth transition protocol. Primary efficacy endpoint was the change from baseline to week 24 in muscle strength. Disability, motor function, and health-related quality of life (HRQL) endpoints were also assessed. One patient deteriorated despite dose increase and was withdrawn. Muscle strength, disability, motor function, and health status were unchanged in all seven study completers who rated home treatment as extremely good. Four experienced 18 adverse events, of which only two were moderate. This study suggests that MMN patients with stable clinical course on regular IVIG can be switched to SCIG at the same monthly dose without deterioration and with a sustained overall improvement in HRQL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available